Positive News SentimentPositive NewsNASDAQ:ELYM Eliem Therapeutics (ELYM) Stock Price, News & Analysis $4.86 -0.15 (-2.99%) (As of 10/17/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About Eliem Therapeutics Stock (NASDAQ:ELYM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Eliem Therapeutics alerts:Sign Up Key Stats Today's Range$4.73▼$4.9750-Day Range$4.86▼$8.4652-Week Range$2.35▼$11.55Volume194,359 shsAverage Volume486,688 shsMarket Capitalization$144.59 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewEliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.Read More… $25,000 into $109,616 in two months? (Ad)Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. Eliem Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks25th Percentile Overall ScoreELYM MarketRank™: Eliem Therapeutics scored higher than 25% of companies evaluated by MarketBeat, and ranked 894th out of 1,012 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Eliem Therapeutics.Read more about Eliem Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Eliem Therapeutics is -9.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eliem Therapeutics is -9.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEliem Therapeutics has a P/B Ratio of 1.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Eliem Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.22% of the float of Eliem Therapeutics has been sold short.Short Interest Ratio / Days to CoverEliem Therapeutics has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Eliem Therapeutics has recently increased by 1.77%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEliem Therapeutics does not currently pay a dividend.Dividend GrowthEliem Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.22% of the float of Eliem Therapeutics has been sold short.Short Interest Ratio / Days to CoverEliem Therapeutics has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Eliem Therapeutics has recently increased by 1.77%, indicating that investor sentiment is decreasing. News and Social Media3.8 / 5News SentimentN/A News SentimentEliem Therapeutics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.Search Interest4 people have searched for ELYM on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows1 people have added Eliem Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Eliem Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,020,062.00 in company stock.Percentage Held by InsidersOnly 4.70% of the stock of Eliem Therapeutics is held by insiders.Percentage Held by Institutions69.76% of the stock of Eliem Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Eliem Therapeutics' insider trading history. Receive ELYM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eliem Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ELYM Stock News HeadlinesEliem Therapeutics (NASDAQ:ELYM) Stock, Short Interest ReportOctober 9, 2024 | benzinga.comEliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.October 2, 2024 | globenewswire.comPublisher makes HUGE discoveryTradingPub Publisher Nate Tucci recently sat down with Chris Pulver to learn about the $100 Challenge. Chris walked him through the trade on a private Zoom call… And he was very clear… This wasn’t a “get rich quick” penny stock scheme… Or an AI stock picker that “cracked the code” of the stock market… It was just a simple, daily trade that anyone could set up at about 9:40 in the morning to target $100 a day or more (starting with just $1,000)...October 18, 2024 | DTI (Ad)Eliem Therapeutics: Recent Strategic Pipeline RestructuringSeptember 23, 2024 | seekingalpha.comEliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation SummitSeptember 11, 2024 | globenewswire.comEliem Therapeutics Announces Additions to its Leadership TeamAugust 26, 2024 | globenewswire.comEliem Therapeutics Reports Second Quarter Financial ResultsAugust 14, 2024 | globenewswire.comInsider Sale at Eliem Therapeutics Inc: EVP, R&D AND CSO Valerie Morisset Sells SharesJuly 24, 2024 | finance.yahoo.comSee More Headlines ELYM Stock Analysis - Frequently Asked Questions How have ELYM shares performed this year? Eliem Therapeutics' stock was trading at $2.70 at the beginning of 2024. Since then, ELYM shares have increased by 80.0% and is now trading at $4.86. View the best growth stocks for 2024 here. How were Eliem Therapeutics' earnings last quarter? Eliem Therapeutics, Inc. (NASDAQ:ELYM) issued its quarterly earnings results on Wednesday, August, 14th. The company reported ($1.81) EPS for the quarter. When did Eliem Therapeutics IPO? Eliem Therapeutics (ELYM) raised $75 million in an initial public offering on Tuesday, August 10th 2021. The company issued 6,000,000 shares at $12.50 per share. SVB Leerink, Evercore ISI, Stifel and Guggenheim Securities acted as the underwriters for the IPO. Who are Eliem Therapeutics' major shareholders? Top institutional shareholders of Eliem Therapeutics include SG Americas Securities LLC (0.04%). Insiders that own company stock include Ra Capital Management, LP, Valerie Morisset and Emily Pimblett. View institutional ownership trends. How do I buy shares of Eliem Therapeutics? Shares of ELYM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Eliem Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eliem Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD). Company Calendar Last Earnings8/14/2024Today10/17/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ELYM CUSIPN/A CIK1768446 Webwww.eliemtx.com Phone877-354-3689FaxN/AEmployees20Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,120,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-47.03% Return on Assets-45.97% Debt Debt-to-Equity RatioN/A Current Ratio60.41 Quick Ratio60.41 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.90 per share Price / Book1.28Miscellaneous Outstanding Shares29,752,000Free Float28,354,000Market Cap$149.06 million OptionableNot Optionable Beta-0.39 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report This page (NASDAQ:ELYM) was last updated on 10/18/2024 by MarketBeat.com Staff From Our PartnersDon’t Buy Another Stock Until Reading This…Buying stocks in today's market is a gamble… Unless you're using the right proven strategy! During my up...Unstoppable Prosperity | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored320 hedge funds just sold this stock320 hedge funds just sold this stock A strange force has seized control of Wall Street. Hedge funds are alr...Chaikin Analytics | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredWar on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adopti...Porter & Company | SponsoredAdd $2T of Potential Magic to Your PortfolioRevolutionizing a whole $2T entertainment and licensing industry might sound like the stuff of fairytales. But...Elf Labs | SponsoredEquation for Profits: Volatility = OpportunityFREE Intro to Options Class Online Tonight Prosper Trading Academy | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eliem Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eliem Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
